Editas Medicine, Inc.: Phase 2 study in Heterozygous Familial Hypercholesterolemia (HeFH) (56 participants)
Editas Medicine, Inc.: Phase 2 study in Heterozygous Familial Hypercholesterolemia (HeFH) (56 participants). Its enrollment of 56 is below the median of 80 (37th percentile). Dated 10 days ago, it is in the active follow-up window. Score 90/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 56 · 37th percentile of 8,879 ClinicalTrialStartPulse records · 0.7x the median
Free preview: all 14 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Editas Medicine, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C) |
| NCT ID | NCT07894887 |
| Phase | Phase 2 |
| Status | not yet recruiting |
| Conditions | Heterozygous Familial Hypercholesterolemia (HeFH) |
| Intervention types | drug, other |
| Target enrollment | 56 |
| Site countries | Australia |
| Posted | 2026-10-26 |
| Planned start | 2026-11 |
| Event | Newly registered study |
| Event date | 2026-10-26 |
| enrollment percentile | 37th of 8,879 (median 80, 0.7x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Editas Medicine, Inc.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Editas Medicine + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-26
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Editas Medicine, Inc. and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Editas Medicine, Inc.'s enrollment: 37th percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
90 / 100 Score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Phase 2: multi-site, larger budget.
- Not yet recruiting: vendors still being chosen.
What is the ClinicalTrialStartPulse record for Editas Medicine, Inc.?
Editas Medicine, Inc. registered a Phase 2 study (NCT07894887) in Heterozygous Familial Hypercholesterolemia (HeFH) targeting 56 participants, posted 2026-10-26.
How does Editas Medicine, Inc. compare to other ClinicalTrialStartPulse records?
Its enrollment of 56 is below the median (37th percentile); smaller records often move faster and face less competition. It is fresh: dated 10 days ago, inside the window where early outreach matters most. Its Score of 90/100 puts it among the stronger signals in this feed.
Editas Medicine, Inc. vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Editas Medicine, Inc. | NONUS | 56 | 37th | 2026-10-26 |
| BeOne Medicines | NONUS | 100 | 60th | 2026-11-03 |
| Nurix Therapeutics, Inc. | US | 150 | 71st | 2026-11-03 |
| Janssen Research & Development, LLC | US | 166 | 73rd | 2026-11-03 |
Related records
- Nurix Therapeutics, Inc.
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Teva Branded Pharmaceutical Products R&D LLC
- Genmab
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Apogee Therapeutics, Inc.
- Janssen Research & Development, LLC
- BeOne Medicines
ClinicalTrialStartPulse: Phase 2 ClinicalTrialStartPulse: Outside the US only
How to monitor Editas Medicine, Inc. and peer phase 2 records
Get new ClinicalTrialStartPulse records like Editas Medicine, Inc. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.